Questions with the most recent answer or edit.
What I have: a GLP-1 receptor agonist · 4 mg/mL · two weeks. I am asking for verification rather than opinion, ideally with something I can read myself. It is…
The specifics, since they change the answer: QST · liraglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is…
I have started asking labs for "the system suitability data" and getting back either silence, a shrug, or a screenshot of six retention times. I clearly do not know…
The particulars: 15 mg · 2 mL · phosphate-buffered diluent · orforglipron. I would like to define my thresholds before I have a result, for obvious reasons. I want a…
For reference: a 1 mL luer-lock syringe · 20 mg · 20 mg/mL. I would rather understand the derivation than memorise the outcome. Two people I asked gave two answers…
Details up front: QST · Wuhan Wansheng Biotechnology. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know…
Stated plainly: QSC · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
Setup, so nobody has to ask: cagrilintide · purity figure. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
Details up front: phosphate-buffered diluent · five days. I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has…
What I am working with: orforglipron · 8 mg/mL · sixteen weeks. This is asserted often enough that I assumed it was established, and then I went looking for the…
What I am working with: orforglipron · 95.2%. I have worked this out and I would like someone to find the error, because I suspect there is one. My working so far,…
The case in front of me: 98.4% · VendorInvestigate · 95.2%. I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact. I want…
Conditions: semaglutide · SELECT. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how confident…
What I have: 99.1% · retatrutide. I can do the algebra. I am not confident about the conversion factors. If there is a standard way to lay this out, I would rather…
The case in front of me: fatigue · retatrutide. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I…
What I am working with: SURMOUNT-1 · dizziness. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
Conditions: HJ · Shanghai Wibson Biotechnology. I would like the axes of comparison first and the recommendation second. I have tried the first option and it works;…
What I have: mazdutide · six weeks · 40 °C. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…
The specifics, since they change the answer: PIONEER-4 · headache · 14 mg. I have the document in front of me and I can read the numbers. What I cannot do is…
SOUL tested oral semaglutide 14 mg daily in people with type 2 diabetes and either atherosclerotic cardiovascular disease or chronic kidney disease, and reported a…
The specifics, since they change the answer: PIONEER-1 · 7 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My…
Stated plainly: a 27G needle · cagrilintide · 6.67 mg/mL. Both of these get recommended confidently by different people, which suggests neither is obviously right. My…
Concretely: survodutide · 12.5 mg. Please show the division. I want to check my own against yours. I would like the general form as well as the specific number, so I…
This is my second independent submission on material from the same supplier. I am trying to choose between two options that are usually discussed as though only one…